CIK 0001819576 · Non-accelerated filer
Liquidia Corp
Sign in to watch- Ticker
- LQDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851710962
- Phone
- 919.328.4400
- Business address
- 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $23,494,367
- in 17 filings, $12.2M under 10b5-1 plans
Net −$23,494,367. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-21 | Adair Jason Chief Business Officer | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −238 | 0 | ||
| 2026-08-20 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 | +11,727 | $2.51 | $29K | 56,364 |
| 2026-08-20 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 | +6,666 | $2.59 | $17K | 63,030 |
| 2026-08-20 | Rielly-Gauvin Katherine Director | Sale 10b5-1 | −18,393 | $72.23 | $1.3M | 44,637 |
| 2026-08-20 | Rielly-Gauvin Katherine Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −11,727 | 0 | ||
| 2026-08-20 | Rielly-Gauvin Katherine Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −6,666 | 0 | ||
| 2026-08-19 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 | +23,455 | $2.51 | $59K | 68,092 |
| 2026-08-19 | Rielly-Gauvin Katherine Director | Option exercise 10b5-1 | +13,334 | $2.59 | $35K | 81,426 |
| 2026-08-19 | Rielly-Gauvin Katherine Director | Sale 10b5-1 | −36,789 | $74.99 | $2.8M | 44,637 |
| 2026-08-19 | Rielly-Gauvin Katherine Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −23,455 | 11,727 | ||
| 2026-08-19 | Rielly-Gauvin Katherine Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −13,334 | 6,666 | ||
| 2026-08-19 | Saggar Rajeev Chief Medical Officer | Option exercise | +50,000 | $3.73 | $187K | 192,265 |
| 2026-08-19 | Saggar Rajeev Chief Medical Officer | Sale | −50,000 | $74.06 | $3.7M | 142,265 |
| 2026-08-19 | Saggar Rajeev Chief Medical Officer | Option exercise · Non-Qualified Stock Option (right to buy) | −50,000 | 150,000 | ||
| 2026-08-17 | Saggar Rajeev Chief Medical Officer | Sale | −29,534 | $76.84 | $2.3M | 142,265 |
| 2026-07-27 | Boyle Dana Chief Accounting Officer | Sale 10b5-1 | −1,600 | $87.53 | $140K | 167,919 |
| 2026-07-27 | Adair Jason Chief Business Officer | Sale 10b5-1 | −688 | $87.53 | $60K | 216,438 |
| 2026-07-23 | Bloch Stephen M Director | Sale | −96,400 | $89.44 | $8.6M | 505,077 |
| 2026-07-23 | Bloch Stephen M Director | Sale | −3,600 | $90.71 | $327K | 501,477 |
| 2026-07-22 | Bloch Stephen M Director | Sale | −37,406 | $87.70 | $3.3M | 664,071 |
Page 4 of 18 · 344 trades